Rising Unwanted Pregnancies Fuel Growth In The Hormonal IUD Market Driver: Leading Transformation in the Hormonal Intrauterine Devices (IUDs) Market in 2025

What market dynamics are playing a key role in accelerating the growth of the hormonal intrauterine devices (iuds) market?
The anticipated surge in unexpected pregnancies is poised to boost the expansion of the hormonal intrauterine devices market in the future. Unexpected pregnancies are those which are neither planned nor desired at the point of conception. They can happen due to several reasons such as failure of contraception, restricted access to birth control, misuse of contraception, or sexual abuse. The lack of effective contraception access exacerbates the risk of unexpected pregnancies by compromising individuals' autonomy over their reproductive choices. Hormonal IUDs are exceptional at preventing pregnancy, boasting a failure rate of less than 1%. They offer extended protection (3 to 7 years, according to the type) and stand as a dependable choice for those desiring to evade unexpected pregnancies. For instance, as per the Office for Health Improvement & Disparities, a UK governmental body within the Department of Health and Social Care, between January and June 2022, there were 123,219 abortions in England and Wales, indicating a 17% rise compared to the corresponding period in 2021. Consequently, the surge in unexpected pregnancies is fueling the growth of the hormonal intrauterine devices market.

Get Your Hormonal Intrauterine Devices (IUDs) Market Report Here:
https://www.thebusinessresearchcompany.com/report/hormonal-intrauterine-devices-iuds-global-market-report

How will the growth rate of the hormonal intrauterine devices (iuds) market shape industry trends by 2034?
The market for hormonal intrauterine devices (IUDs) has seen significant growth in recent years, forecasted to expand from $2.61 billion in 2024 to $2.89 billion in 2025, reflecting an 11.0% compound annual growth rate (CAGR). The acceleration in growth during this historic period can be credited to the advent of safer and more efficient hormonal solutions, boosted demand for persistent contraceptive methods, increased recommendations from healthcare professionals, heightened public consciousness about birth control choices, and progression in medical technology and device development.

The market for hormonal intrauterine devices (IUDs) is predicted to experience a significant surge in the upcoming years, expanding to a value of $4.34 billion by 2029 with a compound annual growth rate (CAGR) of 10.7%. Factors credited for this estimated growth during the forecast period include increased understanding of contraception options, a growing fondness for long-acting reversible contraception, improvements in device safety and performance, a heightened focus on personalized healthcare, and wider access through health service providers. Key trends during this forecast period encompass advancements in device innovation, personalization of contraceptive methods, patient-oriented healthcare approaches, increasing demand for eco-friendly and sustainable products, and the introduction of new contraceptive products.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19091&type=smp

What trends are poised to drive the future success of the hormonal intrauterine devices (iuds) market?
The primary corporations in the hormonal intrauterine devices sector are looking to develop cutting-edge products such as levonorgestrel-releasing intrauterine systems, in order to offer more customized contraceptive options for females. Levonorgestrel-releasing intrauterine systems (LNG-IUS), a type of hormonal intrauterine device, releases a consistent dosage of levonorgestrel, an artificial progestin, into the uterus. This hormone induces the thickening of cervical mucus and manipulates the uterine lining, blocking sperm from making contact with the egg. In November 2022, for instance, Medicines360 - an American pharmaceutical firm with a commitment to enhancing women's access to vital medicines and health items - launched LILETTA, an FDA-approved product. LILETTA stands as one of the most durable hormonal IUDs in the U.S., sanctioned for up to 8 years for contraceptive use and up to 5 years for the management of heavy menstrual bleeding. It boasts approximately a 99% success rate in preventing pregnancies across various demographics. The device's design features an ergonomic inserter for hassle-free placement on the day of consultation and allows for removal by a health professional at any time. LILETTA, which requires prescription, is offered at a lower rate through the 340B drug pricing scheme in alignment with Medicines360's goal of enhancing women's healthcare accessibility.

Which primary segments of the hormonal intrauterine devices (iuds) market are driving growth and industry transformations?
The hormonal intrauterine devices (IUDs) market covered in this report is segmented -

1) By Type: 13 Milligram Hormonal Intrauterine Devices, 19 Milligram Hormonal Intrauterine Devices, 52 Milligram Hormonal Intrauterine Devices
2) By Device Design: Framed Intrauterine Devices, Frameless Intrauterine Devices
3) By Hormone Type: Levonorgestrel Releasing Intrauterine Devices, Progesterone Releasing Intrauterine Devices
4) By Application: Age 20-24, Age 25-34, Age 35-44, Other Applications

Subsegments:
1) By 13 Milligram Hormonal Intrauterine Devices: Low-Dose 13 Mg IUDs, Specialty 13 Mg IUDs For Specific Conditions
2) By 19 Milligram Hormonal Intrauterine Devices: Low-Dose 19 Mg IUDs, Specialty 19 Mg IUDs For Specific Conditions
3) By 52 Milligram Hormonal Intrauterine Devices: Standard 52 Mg IUDs, Extended-Release 52 Mg IUDs, Specialty 52 Mg IUDs For Heavy Menstrual Bleeding Or Endometriosis

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19091

Which geographical regions are pioneering growth in the hormonal intrauterine devices (iuds) market?
North America was the largest region in the hormonal intrauterine devices (IUDs) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormonal intrauterine devices (IUDs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the hormonal intrauterine devices (iuds) market landscape?
Major companies operating in the hormonal intrauterine devices (IUDs) market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Organon & Companies, Gedeon Richter Plc, Meril Life Science Pvt Ltd., Bharat Serums and Vaccines Limited, Teva UK Limited, EurimPharm Produktions GmbH, HRA Pharma SAS, Medicines360, Hll Lifecare Limited, Pregna International Ltd., Allergan plc, Actavis Inc., DKT WomanCare Global, CrossBay Medical Inc., SMB Corporation of India, Oy Leiras, OCON Healthcare

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19091&type=smp

What Is Covered In The Hormonal Intrauterine Devices (IUDs) Global Market Report?

•Market Size Forecast: Examine the hormonal intrauterine devices (iuds) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the hormonal intrauterine devices (iuds) market for a structured understanding.
•Key Players Overview: Analyze major players in the hormonal intrauterine devices (iuds) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the hormonal intrauterine devices (iuds) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the hormonal intrauterine devices (iuds) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the hormonal intrauterine devices (iuds) market.
•Industry Challenges: Identify potential risks and obstacles affecting the hormonal intrauterine devices (iuds) market.
•Competitive Landscape: Review strategic developments in the hormonal intrauterine devices (iuds) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.